Halozyme Therapeutics — Aug 6, 2026 release

Overall, these results illustrate our continued ability to create multiple waves of revenue opportunities that will drive long-term shareholder value,” concluded Dr. Torley. Second Quarter Corporate Highlight: • In May 2026, the Company announced a new share repurchase program to repurchase up to $1.0 billion of its outstanding common stock by December 31, 2028, with an expectation of buying back at least $400 million of shares in 2026. During the second quarter of 2026, the Company repurchased 4.8 million shares for $332.8 million at an average price of $69.30 per share under the May 2026 and February 2024 share repurchase programs. The February 2024 share repurchase program was completed in June 2026. Recent Partner Highlights: • In July 2026, Halozyme and Incyte entered into a global collaboration and license agreement to evaluate additional subcutaneous formulations of INCA033989, a first-in-class mutant calreticulin (“mutCALR”)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (“MPNs”), utilizing Halozyme’s proprietary ENHANZE ® drug delivery technology. Under the collaboration, Incyte also has the option to nominate up to two additional targets for use with ENHANZE ® . Under the terms of the agreement, Incyte agreed to make an upfront payment and potential future milestone payments and royalties on net sales of products developed with ENHANZE ® . • In the third quarter of 2026, the ongoing ARGX-119 adimanebart program was expanded to include a Phase 1 SC bioavailabil